- Dr. Abribat has a proven track record of developing innovative treatments for rare diseases, achieving three successful biotech/company exits
- He is a seasoned scientific and operational leader, having held senior roles in drug development and business development
- He joins the Azafaros Board as the company advances two Phase 3 pivotal studies with its lead asset nizubaglustat in Niemann-Pick Type C disease (NPC) and GM1/GM2 gangliosidoses
Azafaros, a company building a portfolio to become a leader in lysosomal storage disorders with the goal of addressing neurological symptoms, today announced the appointment of experienced biotech executive and entrepreneur, Thierry Abribat, to the company’s Board of Directors.
Dr. Abribat is a seasoned biotech entrepreneur and executive with more than 25 years’ experience in advancing innovative therapies, from early research through late-stage clinical development and commercialization. He was founder and CEO of global biopharmaceutical company, Amolyt Pharma, which advanced multiple programs for rare endocrine diseases through clinical and preclinical development before being acquired by AstraZeneca in 2024 for more than a billion dollars. Prior to that, he founded and led Alizé Pharma and Alizé Pharma 2, successfully building and exiting both rare disease companies.
“Thierry brings a combination of scientific depth, strategic vision, and a proven track record of value creation in biotech,” said Carlo Incerti, Chairman of the Board of Directors at Azafaros. “Azafaros is enrolling two registrational Phase 3 studies with our lead product nizubaglustat. Thierry will bring valuable insight as we move into our next phase of the company, with a potential commercialization stage in sight following regulatory approval.”
Dr. Abribat added: “I am delighted to join Azafaros at such an exciting stage of development. The company’s science is compelling, and with my experience in company building and advancing innovative therapeutics for rare diseases, I look forward to contributing so that we can deliver on our mission/strategy to bring important new therapies to patients.”
Dr. Abribat earned a doctorate in veterinary medicine and a PhD in neuroendocrinology from the National Polytechnic Institute of Toulouse and began his career as a scientist at Sanofi and at the University of Montreal.
Explore the Business Insights Journal for up-to-date strategies and industry breakthroughs!
